Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001 | 0.80 | CYP2D6 (0.52) | CYP2D6CYP2C19 | |
| SCHEMBL4885972 | 0.77 | CYP2D6 (0.38) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL838330 | 0.75 | CYP2D6 (0.37) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL22076985 | 0.75 | CYP2D6 (0.37) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL28757855 | 0.75 | — | — | |
| SCHEMBL3189914 | 0.71 | GABRP (0.44) | CYP2D6CYP2C19MEN1KMT2A | |
| SCHEMBL667964 | 0.70 | — | — | |
| SCHEMBL4352303 | 0.69 | MEN1 (0.43) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL5933309 | 0.69 | CYP2D6 (0.40) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL1923786 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066287-A1 | PHASE CHANGE AROMATIC AZO COMPOUNDS, METHOD OF MANUFACTURE, AND USE AS HOMOGENOUS CATALYST | BRANDEIS UNIVERSITY | 2025-02-27 | — | — | US | disclosed |
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-01-15 | — | — | US | disclosed |
| US-9655906-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-05-23 | — | — | US | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| EP-3154934-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015193255-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-23 | — | — | WO | disclosed |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-9120801-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| EP-2556074-B1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | ACRAF (IT) | 2015-01-21 | — | — | EP | disclosed |
| EP-2556074-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. (IT) | 2013-01-24 | — | — | US | disclosed |
| WO-2011124430-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-10-13 | — | — | WO | disclosed |
| WO-2004012506-A2 | ANTIMICROBIAL COMPOUNDS | EXEGENICS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | CYP2D6 11/4885CYP2C19 4/4885MEN1 1692/4885 |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | CYP2D6 246/4885CYP2C19 367/4885MEN1 2161/4885 |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | CYP2D6 246/4885CYP2C19 367/4885MEN1 2161/4885 |
| US-20250066287-A1 | PHASE CHANGE AROMATIC AZO COMPOUNDS, METHOD OF MANUFACTURE, AND USE AS HOMOGENOUS CATALYST | CTSV, CTSS, CMA1 | CYP2D6 222/4885CYP2C19 235/4885MEN1 1745/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | CYP2D6 246/4885CYP2C19 367/4885MEN1 2161/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | CYP2D6 246/4885CYP2C19 367/4885MEN1 2161/4885 |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | CYP2D6 11/4885CYP2C19 4/4885MEN1 1692/4885 |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | CYP2D6 246/4885CYP2C19 367/4885MEN1 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.